NATS: Multivirus-specific T-cells for Viral Infections Post-HSCT

Phase 1, open-label trial of virus-specific T cells in viral infection and bone marrow transplant infection (2 arms), sponsored by Children's National Research Institute. Primary endpoints: Incidence of acute GvHD (grade III-IV) at 45 days and Incidence of adverse events as per CTCAE common criteria guidelines at 45 days. Started Feb 2017; status: active, not recruiting.